Editas Medicine, Sandhill announce collaboration for engineered cell medicines
Editas Medicine and Sandhill Therapeutics announced a strategic research collaboration, license, and option agreement to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture allogeneic engineered natural killer cells and non-alpha beta T cell medicines for the treatment of cancer. This collaboration brings together Editas Medicine's leading genome editing technology and Sandhill's BINATE product process, a novel universal donor technology to extract, isolate, and expand NK cells and non-alpha beta T cells, to develop novel medicines for the treatment of solid tumor cancers. Under the terms of the agreement, Editas Medicine obtains an exclusive license to Sandhill's technology to research, develop and commercialize immuno-oncology engineered cell medicines for solid tumors originating within a given area of the body and an option to expand such license to two additional areas. In return, Sandhill will receive an upfront payment, development and sales-based milestone payments, and royalties on sales of resulting Editas products.